Spring Break: Novo's US Head Resigns After Rough Winter
Novo Nordisk's executive VP and head of North American operations, Jakob Riis, has resigned from the company – a move not completely out of the blue considering recent rumors of conflict within the diabetes drug developer's US operations and a lackluster 2016 financial performance for the whole group.
You may also be interested in...
As US prosecutors investigate Novo Nordisk and other insulin makers for their pricing and contracts with pharmacy benefit managers, plaintiff firms allege the Danish group engaged in collusive agreements and misled investors about its earnings and forecasts.
Lars Rebien Sørensen is retiring as CEO of Novo Nordisk by the end of the year, with executive vice president and corporate development head Lars Fruergaard Jørgensen stepping up as his successor.
Jakob Riis is a Danish national who joined diabetes R&D giant Novo Nordisk in 1996 as a health economist. He has since risen through the company, via a series of marketing roles of increasing seniority, to take on his current position of executive vice-president of China, Pacific and marketing.